Company Information
CIN
Status
Date of Incorporation
01 March 1993
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
28 August 2023
Paid Up Capital
2,399,300,000
Authorised Capital
6,000,000,000
Directors
Meetal Sampat
Director/Designated Partner
about 2 years ago
about 2 years ago
Rolf Karl Heinz Hoffmann
Director/Designated Partner
over 2 years ago
over 2 years ago
Gautam Bhailal Doshi
Director/Designated Partner
over 2 years ago
over 2 years ago
Sudhir Vrundavandas Valia
Director/Designated Partner
over 2 years ago
over 2 years ago
Sailesh Trambaklal Desai
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Sanjay Khatau Asher
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Anoop Anjanikumar Deshpande
Nodal Officer
almost 4 years ago
almost 4 years ago
Rama Bijapurkar
Director/Designated Partner
over 4 years ago
over 4 years ago
Pawan Kumar Goenka
Director/Designated Partner
over 4 years ago
over 4 years ago
Vivek Chaand Sehgal
Director
about 7 years ago
about 7 years ago
Kalyanasundaram Iyer Natesan Subramanian
Director/Designated Partner
about 8 years ago
about 8 years ago
Chinnadharavaram Sundaresan Muralidharan
Cfo
over 8 years ago
over 8 years ago
Rekha Praveen Sethi
Director
about 11 years ago
about 11 years ago
Dilip Shantilal Shanghvi
Director/Designated Partner
over 17 years ago
over 17 years ago
Keki Minoo Mistry
Director
over 23 years ago
over 23 years ago
Past Directors
Aalok Dilip Shanghvi
Additional Director
over 2 years ago
over 2 years ago
Ashok Indulal Bhuta
Deputy Nodal Officer
about 6 years ago
about 6 years ago
Israel Makov
Director
about 13 years ago
about 13 years ago
Sunil Roshanlal Ajmera
Company Secretary
over 14 years ago
over 14 years ago
Ashwin Suryakant Dani
Director
almost 22 years ago
almost 22 years ago
Kamlesh Hiralal Shah
Company Secretary
almost 23 years ago
almost 23 years ago
Hasmukh Shantilal Shah
Director
over 24 years ago
over 24 years ago
Subhagmal Mohanchand Dadha .
Director
over 28 years ago
over 28 years ago
Patents
The present invention relates to fingolimod hydrochloride sucrose adducts and process of preparation thereof. In preferred embodiments the adduct is a compound of formula (Ib),
The present invention relates to controlled release coated tablets that retain their size at least along one dimension and thereby retained for longer period in the stomach.
The present invention provides a stable pharmaceutical composition comprising gabapentin and pharmaceutically acceptable adjuvants, wherein the composition has an alkaline pH, and wherein at least one of the pharmaceutically acceptable adjuvants is a destabilizer.
The present invention relates to a process for the preparation of 5-[[4-(5-ethy]-2-pyridinyl) ethoxy]ethoxy]pheny]mehtyl]-2,4-thiazolidinedinedione commonly known as pioglitazone (INN Name), compound of formula 1, is used in the management of type 2 diabetes.
The present invention discloses a process for the preparation of a compound of formula I wherein R1 is a lower alkyl that may be linear or branched or cyclic; allyl. propargyl or benzul; R2 is hydrogen or lower alkyl; R3 is hydrogen or lower alkyl or R2 and R3 together with the nitrogen to which they are attahced ma...
The present invention provides a novel process for preparation of trans-3-ethyl 2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide via the novel intermediate compounds of formula 3.
The present invention provides a process for the manufacture of free-flowing unformly sized microspheres or microcapsules for the sustained release of therapeutically active ingredient, the process comprising: a. preparing a first dispersed phase comprising a therapeutically active ingredient, a biodegraded polymer ...
PROCESS FOR PREPARATION OF A GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM
The present invention provides a dry powder inhaler for administering medicaments in solid finely cividedfopm to patients, wherein the dry powder inhaler is in the form of an improved diskhaler, wherein the improvement comprises replacment of two unites, the first being a iorarable support and second being an annula...
The present invention provides a sustained release microsphere composition comprising-
(i)microspheres comprising(A)a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid glycolic acid having a monomer of goserelin or range of about 1:1 to about 3:1 and(B)a therapeutically effe...
A process for the preparation of (1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthylamine, compound of formula 1,
said process comprising
(a) reacting 4-(3,4-dichlorphenyl)-3,4-dihydro-1(2H)-napthalenone, compound of formula 2, with methylamine in an or cyclic polyether as herein defined, to yield...
A process for the preparation of1,4-dihydropyridine-3,5-dicarboxylic acid derivative of formula I and anantiomers comprising reacting compound of formula III with compound of formula IV to yield1,4-dihydropyridine-3,5-dicarboxylic acid derivative of formula I and its pharmaceutically acceptable salt.
...
The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib. The present invention provides an environmentally friendly cost effective and ind...
The present invention relates to crystalline form II of memantine hydrochloride Memantine hydrochloride is used in the treatment of Alzheimer's & Parkinson's disease.
The present invention provides a sustained release microsphere composition comprising - (i) microspheres comprising (A) a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 to 3:1, and (B) a therapeutically effe...
A dry powder inhaler comprising
(a) a housing
(b) a carrier mounted in the housing, adapted to receive a rotatable support disk
(c) a rotatable support disk adapted to receive a blister pack containing powder medicament
(d) a blister pack
(e) a plunger to rupture a blister container registered therewith
(f) at...
A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients a...
A regiospecific process for the preparation of 4-[1-(4-cyanophenyl)-1-(1,2,4-triazol-1-yl) methyl]benzonitrile comprising reacting 4-halomethylbenzonitrile with 4-amino-1,2,4-triazole followed by deamination and reaction with 4-fluorobenzonitrile.
The present invention provides a sustained releasse microsphere composition comprising-
(i)microsphere comprising (A)a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 about 3:1, and(B)a therapeutically effec...
The present invention provides a controlled release antidiabetic composition comprising a compressible controlled release core composition comprising metformin or its pharmaceutically acceptable salt, two or more swellable polymers wherein at least one polymer is an anionic polymer, one or more pharmaceutically acce...
A dosage from for treatment of diabetes mellitus and condition associated with it comprising a combiniation of biguanide and long-acting sulfonyl urea such that the long-acting sulfonyl urea is released immediately and the biguanide is released in a controllwed manner.
The present invention relates to controlled release pharmaceutical dosage forms comprising a solid dispersion of a poorly water soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled release d...
The present invention provides an improved process for the preparation of compound of formula III by cyclizing compound of formula II in presence of hexamethyldisilazane and a base in a solvent. The compound of formula III is further converted to Idelalisib.
The present invention relates to a dual chamber pack for a multi dose oral liquid pharmaceutical composition wherein the compositions of the first and second chambers are mixed at the time of first administration.
The present invention relates to a process for the preparation of palbociclib utilizing a silyl protected crotonic acid derivative to produce a silyl protected 2 chloro 4 (cyclopentylamino) 5 (1 methyl 2 carboxy ethen 1 yl)pyrmidine followed by intramolecular cyclization of the pyrmidine intermediate to produce 2 ch...
The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
The present invention provides crystalline Form I Form II Form III Form IV Form V Form V A Form VI Form VII and Form VIII of palbociclib processes for their preparation pharmaceutical compositions comprising these crystalline forms and their use for the treatment of cyclin dependent kinase associated diseases.5
...
The present invention relates to a stable topical pharmaceutical composition comprising nanonized silver sulfadiazine wherein the composition is substantially free of preservatives or antioxidants.
The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3...
A dosage form having a composition comprising nilotinib butanedisulphonate (2:1) or nilotinib butanedisulphonate (1:1) wherein each unit of the dosage form contains 50 to 250 mg of nilotinib.
The present invention relates to crystalline forms of ibrutinib, designated as Form S1, Form S2, Form S3, Form S4, and an amorphous form, designated as Form A1, and processes for their preparation, pharmaceutical compositions comprising these forms, and their use for the treatment of Bruton"s tyrosine kinase (BTK) m...
A sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective ...
A compact sustained release tablet comprising divalproex or its pharmaceutically acceptable salts as a sole active ingredient is present in an amount equivalent to from about 700 mg to about 1500 mg of valproic acid and pharmaceutically acceptable tablet excipients; wherein weight ratio of pharmaceutically acceptabl...
The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
The present invention relates to a capsule composition of raloxifene comprising multiparticulates comprising a) a core comprising raloxifene, and b) a taste masking coating present in amount of 0.5% to 40%w/w based on the core weight.
The present invention relates to a stable extended release composition of cefpodoxime proxetil and a process for its preparation. The composition comprises cefpodoxime proxetil a stabilizer and a release controlling agent wherein the composition is characterized by having a pH of less than about 4. The composition i...
The present invention provides a transdermal delivery system comprising:
i. a drug-containing matrix layer comprising: methylphenidate base; an adhesive polymer made up of a styrene rubber block copolymer having a styrene content of 24 % or above by weight of the adhesive polymer, the adhesive polymer is present i...
The present invention relates to composition of iron sucrose and process for its preparation. The present invention also related to a process for the preparation of iron sucrose suitable for the iron sucrose composition.
The present invention provides a process for the preparation of baricitinib and an intermediate thereof. The present invention provides a convenient economical and industrially advantageous two step process for the preparation of [4 (IH pyrazol 4 yl) 7Hpyrrolo[2 3 d] pyrimidin 7 yl]methyl pivalate of Formula (II). T...
The present invention belongs to the pharmaceutical field and relates to a sterile, injectable, ready-to-administer solution of fentanyl or a salt thereof whose utility lies in treating patients in need of therapy with fentanyl or a salt thereof, such as patients suffering from pain, patients undergoing a surgical p...
The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and fu...
The present invention relates to processes for the preparation of an active pharmaceutical ingredient consisting essentially of amorphous apremilast.
The present invention provides a sterile solution comprising octreotide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in multiple daily doses and f...
The present invention relates to a dual chamber pack with a first chamber comprising a container; and a second chamber comprising a reservoir a biphasic connector a plunger and a plug with a breakable polymeric membrane. The container of the first chamber is prefilled with a pharmaceutically acceptable vehicle and t...
The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time.
A method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration.
The present invention relates to an amorphous solid dispersion comprising selexipag and corn starch and process for preparation thereof.
The present invention provides a process for the preparation of enzalutamide.
The present invention relates to stabilized gastroretentive tablets comprising pregabalin,
one or more swellable polymers, a pH modifier, and other pharmaceutically acceptable
excipients. It also relates to processes for the preparation of said stabilized gastroretentive
tablets of pregabalin.
...
The present invention relates to a stable infusion dosage form of morphine or its pharmaceutically acceptable salt which is stable upon autoclaving and has long term stability.
There is a need in the art for a stable infusion dosage form of morphine which is terminally sterilized and can withstand the harsh condit...
The present invention provides a 1:1 salt of dabigatran etexilate with 1,4-butanedisulfonic acid, its crystal form and process for its preparation.
The present invention provides a solid dosage form comprising two active pharmaceutical agents; acetylsalicylic acid and clopidogrel or pharmaceutically acceptable salts thereof, wherein the total amount of these active pharmaceutical agents present in the solid dosage form is more than 55% of the total weight of th...
The present invention relates to a novel and improved process for the preparation of lacosamide, wherein the process is a sequential one-pot process.
The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn’s disease.
The present invention provides crystalline Form S of regadenoson which is substantially free of residual organic solvent and having an X-ray powder diffraction pattern comprising characteristic peak at 10.3, 10.8, 19.0, 21.6 and 25.5 ± 0.2 degrees 2?.
The present invention provides an amorphous form of baricitinib, processes for its
preparation, a pharmaceutical composition comprising it, and its use for the treatment of JAKassociated
disease.
The present invention relates to an improved process for preparation of enzalutamide which involves direct condensation of 2-(4-alkoxycarbonyl-3-fluoro-anilino)-2-methyl-propanoic acid and 4-isothiocyanato-2-(trifluoromethyl) benzonitrile to obtain alkyl 4-[3-(4-cyano-3-methyl-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imi...
ABSTRACT
The present invention related to a novel compound of Formula II
,
its enantiomers or acid addition salts thereof and process for its preparation. The compound of Formula II can be used for preparation of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol...
The present invention relates to a dry process for the preparation of pharmaceutical compositions of tofacitinib comprising tofacitinib and one or more pharmaceutically acceptable excipients. Dry processes such as direct compression or dry granulation involve fewer and simpler process steps thus preventing the loss ...
The present invention relates to a stable dispersible formulation of arterolane maleate and
piperaquine, wherein the formulation exhibits enhanced structural integrity and is able to rapidly
disintegrate in water within 3 minutes. The dispersible formulation presents acceptable taste and leaves minimal residue in ...
The present invention provides an oral pharmaceutical composition of isotretinoin with a
reduced dose. The present invention further relates to a process for preparing the oral pharmaceutical
composition of the present invention.
The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multi...
ABSTRACT
The present invention relates to a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts via a novel aziridine intermediate of Formula IV
.
The present invention relates to an extended-release composition of cefuroxime axetil and a process for its preparation.
The present invention relates to processes for the preparation of an ertugliflozin L pyroglutamic acid (1:1) and co crystal ertugliflozin L proline (1:1) co crystal. The present invention further relates to an ertugliflozin L proline (1:2) co crystal processes for its preparation and its use for the treatment of typ...
The present invention relates to a parenteral dosage form comprising a) a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, pH adjusting agent to provide a pH in the range of 3 to 5 and ethanol, and b) an infusion container filled with said aqueous solution.
The ...
The present invention relates to the anti dengue activity of the cissampelos pareira extracts. Pharmaceutical compositions
comprising extracts of cissampelos pareira and processes for the preparation of extracts of cissampelos pareira are also
provided.
The present invention relates to a method of treating acne or psoriasis by topically administering Tazarotene, a compound of formula (I), substantially free of dimer impurity 4,4-dimethyl-6-[4-(4,4-dimethyIthiochroman-6-yl)-buta-l,3-diynyl]-thiochromans a compound of formula (II)
The present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof having the configuration of formula (IA) or configuration of formula (IB) selectively over the other enantiomer.
The present invention relates to an aqueous topical solution comprising a therapeutically active ingredient consisting essentially of olopatadine or its pharmaceutically acceptable salt and a solubilizer selected from a group consisting of tyloxapol, vitamin E tocopheryl polyethylene glycol diesters of dicarboxylic ...
A pharmaceutical composition comprising pramipexole or its pharmaceutically acceptable salts or its hydrates or solvates thereof, sugar alcohol (s) and a pharmaceutically acceptable carrier medium substantially free of polyvinyl pyrrolidone.
The present invention relates to novel hydrazide containing carboxylate derivatives of taxanes and salts thereof for use as chemotherapeutic agents for prevention and treatment of cancer.
The present invention provides a gastric retention controlled drug delivery system comprising a controlled release core comprising a drug, a highly swellable polymer and a gas generating agent, said core being capable of swelling and achieving floatation rapidly while maintaining its physical integrity in gastrointe...
The present invention provides optically pure (S)-(+)-N-methyl-3-(l-naphthaleneoxy)-3-(2-thienyl)propanamine, a compound of formula 1, and optically pure (S)-isomer of compound of formula 4, wherein Ri and R2 both are methyl or R| is methyl and R2 is benzyl or substituted benzyl group and process for preparation the...
In general, this disclosure is directed to circuit for implementation of headswitches and footswitches in an ASIC for power management. The disclosed circuit supports not only effective power management, but also efficient use of ASIC area, reduced complexity, and the use of electronic design automation (EDA) tools....
The present invention relates to 11β-hydroxyandrosta-4-ene-3one, compound of formula I,and physiologically acceptable salt thereof
The present invention provides a novel gastric retention system in the form of a tablet or a capsule coated with an expandable coating, more particularly, with an expandable coating comprising a film-forming polymer and expandable component.
The present invention provides an oral drug delivery system comprising -
a. a core comprising an active ingredient composition comprising therapeutically effective
amount of at least one active ingredient and a pharmaceutically acceptable excipient, and
b. a coating surrounding the core, said coating comprising a...
The present invention relates to a process for the preparation pf a stable lyophilized form of a water insoluble drug suitable for parenteral use and pharmaceutical compositions comprising such lyophilized form of the drug.
The present invention relates to an improved process for preparing morphinane analogues of formula 1 wherein the substituents R1, R2, R2a, R3, R4, R5 and Y have the meanings as defined in the specifications.
The present invention relates to an inclusion complex of Atovaquone or its pharmaceutically acceptable salts and cyclodextrin or its derivatives, wherein the molar ratio of atovaquone to cyclodextrin in the inclusion complex ranges from about 1:2 to 1:5.
A process for preparing of (-)-trans-4-(4-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]piperidine, compound of formula I or pharmaceutically acceptable salts thereof, said process comprising hydrolyzing compound of a formula II, wherein R may be selected from halo substituted or unsubstituted linear or bran...
A process for the preparation of Formula I, comprising reacting compound of Formula II with compound of Formula III in presence of base and catalyst, compound of Formula IV wherein R1, R2, R3, R4, are independently selected from hydrogen, C1-C12 linear or branched or cyclic alkyl, aryl and a alkyl group; and X is hy...
The present invention provides optically pure (S)-(+)-N-methyl-3- (1-naphthaleneoxy)-3- (2-thienyl) propanamine, a compound of formula 1, and optically pure (S)-isomer of compound of formula 4, wherein R₁ and R₂ both are methyl or R₁ is methyl and R₂ is benzyl or substituted benzyl group and process for preparation ...
The present invention provides a process for preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile comprising reacting a compound of formula IVa, in the presence of a base with a compound of formula RX, wherein R is selected from alkyl, alkenyl, aryl and heteroaryl wh...
The present invention relates to pharmaceutical compositions the anti-depressant drug, duloxetine.i"liieric coated, multiparticulate pharmaceutical compositions of the present iincntion may be prepared according to the following process:
a) A dispersion of dtiloxetine hydrochloride is prepared by homogenizing dulox...
The present invention provides a daily method for alleviating signs and symptoms of spasticity in a patient comprising orally administering once-daily controlled drug delivery system comprising an effective amount of baclofen or its pharmaceutically acceptable salt for alleviating signs and symptoms of spasticity wh...
The present invention relates to a sustained release tablet formulation comprising an inner phase comprising a mixture of divalproex or its pharmaceutically acceptable salt and a hydrophobic agent. and an outer phase comprising a hydrophilic polymer, wherein the hydrophobic agent is hydrogenated castor oil and the h...
Crystalline hydrate of hypoglycemic agent, compound of formula I with water content of about 2 to about 7% by weight, and pharmaceutical compositions comprising the same.
A stable, oral, solid dosage form comprising uncoated rosiglitazone acid addition salt, uncoated biguanidc (s).
citric acid and other pharmaceutically acceptable excipients.
To
The Controller of Patents The Patent Office At Mumbai-400 037
A pharmaceutical matrix tablet comprising an admixture of pseudoephedrine or its pharmaceutically acceptable salts and a release rate controlling system which comprises one or more water insoluble diluents, one or more water insoluble polymers and one or more hydrophobic materials
The present invention provides a process for preparation of substantially pure 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, compound of formula I or its pharmaceutically acceptable salt comprising: a) subjecting compound of formula II or acid addition salt thereof to hydrogenolysis in aqueous medium in the pres...
A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 μm to about 26 μm and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said oxcarbazepine and a hydrophilic polym...
The invwention is about the compound 2-bromo-3-[4-[295-ethyl-2-pyridyl0ethoxy]phenyl}propinamide and the process for its preparation, comprising reacting diazonium salt of 4-[2-(5-Erthyl-2-pyridyl) ethoxy] amino-benene, with acrylamide, aqueous HX (wherein X is Br or CI) in the presence of a metal halide.
...
Tthe present invention provides a stable, oral, solid dosage form consisting essential!) of an intimate mixture of therapeutically effective amounts of ainlodipine or its pharmaccutically acceptable salt and therapeutical!) effective amounts ol" olmesartan or its pharmaceutical!) acceptable salt and pharmaceutical!)...
CRYSTALLINE FORM V OF 0-DESMETHYLVENLAFAXINE SUCCINATE, WHEREIN THE CRYSTALLINE FORM EXHIBITS AN X-RAY POWDER DIFFRACTION PATTERN HAVING CHARACTERISTIC PEAKS EXPRESSED IN DEGREES 20 (+-2.2 20) AT 12.15, 13.17, 14.67, 15.8, 19.69, 20.45, 22.27, 24.40, 26.43, 28.44 AND 33.69.
The present invention provides a process for the preparation of amorphous rabeprazole sodium said process comprising
(1) suspending rabeprazole in an organic solvent having dielectric constant ranging
between 1.8 to 21, wherein at least 80% of the organic solvent is a ketonic solvent
having dielectric constant r...
The invention relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier comprising tromethamine and an additional stabilizer in amount sufficient to prevent the degradation of atorvastatin.
The present invention provides a process for the preparation of an antiandrogen compound, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-flurorophenyl)sulfonyl]-2-hydroxy-2methypropanamide, a compound of formula 1, comprising reacting N-[4-cyano-3-(trifluoromethyl)phynyl]-2-methyloxirane-2-carboxamide, a compound of fo...
A PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED ETHYL-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN -4-ONE
A process for the preparation of acetylcholinesterase inhibitor, 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]-methylpiperidine,a compound of formula I or pharmaceutically acceptable salt thereof, comprising reacting 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl]-methylpiperidine, a compound of formula II, with sod...
The invention relates to an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydroxyalkyl-β-cylcodextrin, preferably hydroxypropyl-β-cylcodextrin. The Present invention also relates to an aqueous topical solution comprising a therapeutically effective amount of olopatadine or its pharmace...
A process for preparing 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino ethoxy)benzoyl]benzo[b]thiophene, compound of formula 1, said process comprising deprotecting compound of formula II with base in dimethyl sulfoxide to yield substantially pure compound of formula I with HPCL purity of 99% or more by area and o...
The present invention provides a nicardipine hydrochloride injection composition comprising a single dose comprising:
(a) about 2.5 mg of Nicardipine hydrochloride;
(b) about 20 mg of sorbitol;
(c) a physiologically and pharmaceutically acceptable buffer, in an amount effective to maintain the pH of the compositi...
A process for the preparation of (IS,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine hydrochloride, compound of formula I, as crystalline form I or form V directly from compound of formula II or by treating the free base of compound of formula II with amine hydrochloride salt in suitable solve...
A PROCESS FOR PREPARATION OF l-[9H/-CARBAZOL-4-YLOXY]-3-({2-(2-(METHOXY)PHENOXY)-
ETHYL}-AMINO]-PROPAN-2-OL
The present invention provides a process for preparation of l-[9H-carbazol-4-yloxy]-3-[{2-(2-
(methoxy)phenoxy)-ethyl}-amino]-propan-2-ol, a compound of formula 1 in racemic form or in the form of opticall...
A PROCESS FOR THE PREPARATION OF A TIMED PULSE RELEASE COMPOSITION
The present invention provides a stable oral composition comprising a therapeutically effective amount of desloratadine and a stabilizer selected from the group comprising an antioxidant, a pharmaceutically acceptable organic compound that provides an alkaline pH, an alkali metal salt, or mixtures thereof, and pharm...
A process for the preparation of Diphenylmethylsulfinyl derivatives of formula I comprising
(wherein R1 is selected from hydrogen, C1-12 linear, branched or cyclic alkyl & hydroxy)
reacting compound of formula 5 with compound of formula 7 to yield compound of formula I.
(wherein R=OR' and R' is C1-12 linea...
The present invention provides a pharmaceutical composition of glimepiride comprising milled glimerpiride or its mixture with one or more pharmaceutically acceptable excipients is optimized such that the pharmaceutical composition obtained upon using the milled mixture is bioequivalent with pharmaceutical compositi...
The present invention relates to a process for the preparation of a pharmaceutical composition for the controlled release of an antipsychotic agent comprising mixing clozapine or its pharmaceutically acceptable salts and pharmaceutically acceptable excipients, converting the mixture into a core and optionally coatin...
A process for preparing 4-{N,N-di-n-propylamino) ethyI]-2,3- dihydro-1H- indol-2-one, a compound of formula 1 or salts thereof comprising
a. reacting a compound of formula 8 with hydroxylamine hydrochloride and formic acid to obtain 2-nitro-6-N,N-di-n-propyiaminoethylphenyl acetonitrile, a compound of form...
An oral pharmaceutical composition comprising phenytoin sodium and sodium lauryl sulphate in the amount in the range of 0.01 % to 0.35 % by weight of the composition, said composition when subjected to United States Pharmacopoeia XXX (USP XXX) dissolution method for extended release phenytoin sodium capsules providi...
The present invention disclosed a novel colorin acetylene black having a mean primary particle size from about 5 nm to 50 nm, a low dibutylphthalate absorption less than 210 m1/100g, a tapped density of at least 110 g/l which black is powdery, easily dispersible and capable of providing high jetness and tinting stre...
A process for the preparation of substantially pure l-(aminomethyl)-l-cyclohexaneacetic acid, a compound of formula I i.e. gabapentin
Formula I
comprising
(a) treating the crude gabapentin with an alkali such that the pH of the reaction mixture is at least 7.5; heating the reaction mixture to a t...
The present invention provides a process for preparation of 2-(imidazol-1-yl)-1-hyydroxyethane3-1,1-diphosphonic acid, compound of 1, said process comprising
a) reacting imidazole with chloroacetyl chloride and benzyl alcohol in a homogenous system in one pot to obtain benyl-imidazolylacetate, compound of formula...
Substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone, a compound of formula 1, is prepared by a novel route, which comprises reacting
3-(3,5-dimethylphenoxy)-2hydroxypropylamine, a compound a formula 2, or its acid addition salt with a compound of formula 3,
wherein Y and Z are selected from X, CCI3CO,...
The present invention provides a process for preparation of 1-[3-(dimethyl amino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile with substantially low levels of impurities from crude 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile base, such that the unwan...
compound of formula I
Formula I
wherein X, Y, X' & Y' are selected from hydrogen, halogen, substituted or unsubstituted alkyl (linear, branched or cyclo), aryl, alkyloxy and haloalkyl group; R1, R2, R3 & R4 are selected from hydrogen, substituted or unsubstituted alkyl groups (linear, branched or cyclo), aryl,...
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoandrosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treating 17b-[(N, N-dimethylcarbamoyl)thio]carbonyl-6a,9a-difluoro-11b-hydroxy-16a-meth...
The present invention provides alkaline earth metal salts of S-enabtiomer of 5-methoxy-2- [(4-methoxy-3, 5-dimethyl-2-pyridinylmethyl) sulfinyl]-1H-benzimidazole,substantially free of sulfone impurity, and a process for preparation thereof comprising
a)enatioselective oxidation of the prochiral sulfide,5-methoxy-...
A process for the preparation of an oral controlled relase pharmaceutical composition in the form of oral osmotic system for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases. The process comprises (a) mixing carvedilol or its pharmaceutically acceptable salt or ester, a polyme...
The present invention relates to a stable aqueous composition comprising desmopressin or its other pharmaceutically acceptable salts in a pharmaceutically acceptable carrier, wherein the carrier comprises a buffering agent, a parahydroxybenzoate preservative, and a cosolvent that improves the efficacy of the preserv...
The present invention relates to a process for the preparation of a coated oral controlled release pharmaceutical composition for once-a-day therapy for the treament and prophylaxis of cardiac and circulatory diseases comprising mixing carvedilol or its pharmaceutically acceptable salt or ester and pharmaceutically ...
The present invention provides a process for the preparation of coated sustained release tablets of sodium valproate having a moderate weight and volume, for once-a-day therapy, comprising-
(a) providing a core comprising sodium valproate and pharmaceutically acceptable excipients,
(b) providing a first coating la...
In the known art of manufacturing railway sleepers three types are in vogue. They are (1) Timber Sleeper (2) iron and Steel Sleeper (3) prestressed Cement Concrete Sleeper, The first is used sparingly because of environment degradation and the second one because of high cost. The third is ...
A Process for the preparation of compound of formula 1 or acid addition salt therof is disclosed.
The present invention relates to an improved process for preparing N-methyI-2-[3-
(l-methyl-4-piperidyl)-lH-indol-5-yl]-ethanesulfonamide1 a compound of formula 1 or its acid addition salts.
The present invention provides a pharmaceutical composition comprising metaxalone and pharmaceutically acceptable excipients, characterized in that pharmaceutical composition has enhanced oral bioavailability. The present invention also provides a pharmaceutical composition comprising metaxalone and pharmaceutically...
The present invention relates to an oral controlled release pharmaceutical composition comprising therapeutically effective amount of the alfuzosin or its pharmaceutically acceptable salt, hydrogel polymer and pH dependent polymer that is soluble in water at a pH below about 5.
SUBSTANTIALLY AMORPHOUS FORM OF AN ANTICANCER AGENT AND PROCESS FOR PREPARATION THEREOF
The present invention provides a novel substantially amorphous form of an anticancer agent, namely, 4[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[{4-(3-pyridnyl)-2-pyrimidinly}amino] phenyl] benzamide methanesulfonate, comm...
The present invention provides an immediate release oral pharmaceutical composition comprising a therapeutically effective amount of fexofenadine or its pharmaceutically acceptable salts, a dissolution enhancing amount of a thermomelting binding agent and pharmaceutically acceptable excipients.
...
The present invention provides a process for the preparation of an oral drug delivery system comprising-
a. providing a core comprising an active ingredient composition comprising at least one active ingredient and a pharmceutivcally acceptable excipient,and
b.surrounding the core with a coating,
wherein the ...
SUSBSTANTIALLY AMORPHOUSE FROM OF AN AN ANTICANCER AGENT AND PROCESS FOR PREPARATION THEREOF
The present invention provides a novel substantially amorphous from an anticancer agent, namely, 4-[(4-Methyl-1-piperaziny)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidiny]amino]pheny]benzamide methansulfonate, commo...
NOVEL STABLE POLYMORPHIC FROMS OF AN ANTICONVULSANT
Stable polymorphic froms III,IV and substantially amorphous from of anticonvusant, tiagabine hydrochoride.
The present invention provides a process for preparing compound of formula (I),
A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.
The present invention relates to a pharmaceutical composition comprising fingolimod and a weak acid cation exchange resin in the form of an ion-exchange complex and pharmaceutically acceptable excipients.
A stable oral pharmaceutical composition comprising a therapeutically effective amount of paroxetine or its pharmaceutically acceptable salt and one or more adjuvants that prevent the formation of pink hue upon storage of the composition, wherein the composition is prepared by aqueous granulation.
...
ACETALIZATION PROCESS FOR PREPARATION OF STEROID COMPOUNDS
An oral pharmaceutical comprising isradipine or its pharmaceutically acceptable salt and pharmaceutically acceptable excipients wherein isradipine or its pharmaceutically acceptable salt has a defined particle size.
The present invention relates to improvement in the process of preparation of abiraterone acetate or a pharmaceutically acceptable salt thereof wherein the improvement comprises purifying the crude 3-?-acetoxyandrosta-5,16-diene-17-yl trifluoromethane sulphonate by crystallization from a solvent to obtain acet...
Clopidogrel hydrogen sulphate in the form of a free-flowing powder characterized by agglomerates of crystalline clopidogrel hydrogen sulphate, free of added excipients and having a particle size distribution such that D10 is not less than 75 urn The invention also relates to the process of preparing clopidogrel hydr...
A solid dosage form comprising agglomerates of clopidogrel hydrogen sulphate having a particle size distribution such that D10 is not less than 75 microns and wherein agglomerates of clopidogrel hydrogen sulphate are present in an amount of at least 55 % by weight of the solid dosage form.
The present invention provides substantially pure desloratadine having an HPLC purity greater than 99.5% and having an absorbance less than 0.15 Au at 420 nm for a 5%w/v solution in methanol, which does not show a peak for an impurity at a relative retention time in the range from about 0.85 to about 0.99 (relative ...
(E)-oxime ether derivative of 5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one, compound of formula I
wherein R in formula I is selected from and their pharmaceutically acceptable salts useful as antihistaminic compounds.
The present invention provides a process for the preparation of an oral osmotic controlled drug delivery system comprising-
(a) providing a core comprising a homogeneous mixture of glipizide, a hydrophilic polymer and other pharmaceutically acceptable excipients,
(b) surrounding the core with a semipermeable wall,...
The present invention relates to pharmaceutical composition comprising dimethyl fumarate; an enzyme modulator or a permeation enhancer or both; and one or more pharmaceutically acceptable excipients. It further relates to a pulsatile release pharmaceutical composition comprising dimethyl fumarate and one or more pha...
The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral ...
A process for preparation of substantially pure β isomer of 2’-deoxy-2’,2’- difluorocytidine, compound of formula 1, or its acid addition salt by i. reacting a mixture of α and β isomers of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-l-methane sulfonate, compound of formula 3, having a α : β ratio in the rang...
The present invention relates to a metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop comprising (a) a bottle with a flexible portion on the walls to decrease the internal volume by a fixed volume; (b) a plunger with a fixed stroke for depressing the flexible portion of the walls...
A process for the preparation of the crystalline Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, having stable colour upon storage at ambient conditions, comprising at least two repetitive steps of crystallization from one or more organic solvent by dissolving 2-methyl-4-(4-methy...
N/A
The present invention relates to an intravenous infusion dosage form of pemetrexed or its pharmaceutically acceptable salt, having long term stability.
The present invention provides novel salts of nilotinib and polymorphs thereof. The acid addition salts of nilotinib with butanedisulfonic acid, naphthalenedisulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and hydroxynaphthoic acid, hydrates and anhydrates thereof, particularly 2:1 and 1:1 salts of nil...
The present invention relates to a stable, sterile, ready to administer parenteral dosage form of amiodarone or its pharmaceutically acceptable salt. Particularly, the present invention provides a stable, sterile, ready to administer parenteral dosage form of amiodarone comprising an aqueous solution comprising amio...
A method of stabilizing linaclotide in a solid dosage form, said method comprising
a) preparing a composition of linaclotide, acesulfame and pharmaceutically acceptable excipients and
b) converting the composition into a solid dosage form.
The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherei...
The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation. The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said ca...
ABSTRACT
The invention relates to an infusion container comprising a sterile, ready-to-use, stable aqueous solution of Midazolam or a pharmaceutically acceptable salt thereof, suitable for direct intravenous infusion to a patient in need thereof. The invention also relates to a novel infusion container having plura...
The present invention provides novel process for the preparation of 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino ethyl]-1,2-benzenediol, a compound of formula I or pharmaceutically acceptable salt thereof comprising subjecting 3,4-bis(arylmethyloxy)-N-[3-4-arymethyloxy)-1-methylpropyl]-β-phenethyl amine, a compou...
A process for the preparation of cariprazine hydrochloride (Formula I) by reacting trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexanamine (Formula II) or it's salt with N,N-dimethylcarbamoyl chloride (Formula III) in a biphasic solvent system containing an organic solvent phase and an aqueous phase, ...
The present invention relates to processes for the preparation of eluxadoline and its intermediates.
ABSTRACT
OPHTHALMIC COMBINATION COMPOSITION
An alkyl quaternary ammonium compound free ophthalmic combination composition of a carbonic anhydrase inhibitor drug and a beta-adrenergic antagonist. The composition is useful for treating intraocular pressure in the eye and related conditions.
...
A process for converting the cis (1R,4R), trans (1S,4R), and trans (1R,4S) stereoisomers of sertraline into sertraline comprises, providing an initial reaction mixture which contains at least one of these stereoisomers, converting the sertraline stereoisomers into an imine form of sertraline. The imine form ...
A process for the preparation of 2,3:4,5-bis-O(1-methylethylidene)- β-D-fructopyranose sulfamate, compound of formula I, comprisingReacting compound of formula II with an amine RNH2 wherein R is selected from hydrogen and C1 to C4 alkyl, in solvent selected from the groupConsisting of ketones ni...
The present invention relates to a pharmaceutical gastro retentive solid oral dosage form comprising nilotinib as the active ingredient. The invention is further related to methods of preparing said dosage form.
The present invention relates to pulsatile release dosage forms wherein said dosage forms provide pH independent pulsatile release of a drug after a predetermined lag time. It also relates to processes for the preparation of said pulsatile release dosage forms.
The present invention relates to a stable, injectable solution of pemetrexed or its pharmaceutically acceptable salt having dissolved oxygen content in the range of 0 ppm to 0.2 ppm and process for preparation thereof.
Pemetrexed is unstable in aqueous solution and achieving an injectable aqueous solution of pemetr...
The present invention relates to a process for the preparation of idelalisib or a pharmaceutically acceptable salt thereof, via a novel intermediate namely, 2-fluoro-6-[[(2S)-2-[[9-(methoxymethyl)purin-6-yl]amino]butanoyl]amino]-N-phenyl-benzamide.
The present invention relates to a process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine, an intermediate for the preparation of apremilast via a compound of Formula V
wherein R is (C1-C4)alkyl, (C1-C4)haloalkyl, -O(C1-C4)alkyl, or –O-benzyl, and L is a leaving group.
...
The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release controlling polymer wherein ...
The present invention relates to extended release suspension compositions of an active ingredient. Said extended release suspension compositions comprise multiple coated cores of the active ingredient and a suspension base wherein the suspension base generates a hypertonic condition such that there is no substantial...
The present invention relates to pharmaceutical compositions comprising a solid dispersion
of dapagliflozin and one or more pharmaceutically acceptable excipients, and processes for their
preparation. It further relates to a method of treating diabetes using said pharmaceutical
compositions.
...
The present invention provides a crystalline Form I of afatinib dimaleate its process for preparation and pharmaceutical composition thereof and its use in the treatment of metastatic non small cell lung cancer.
The present invention provides processes for the preparation of ibrutinib intermediate compounds of Formula VI and Formula VIII and salts thereof. The processes of the present invention are commercially viable cost effective environmentally friendly and make use of inexpensive non hazardous safe chemicals that are e...
The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled...
A method of determining bioequivalence of a generic linaclotide drug to the corresponding original linaclotide drug.
The present invention provides a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is prese...
PROCESS FOR THE PREPARATION OF NILOTINIB
The present invention relates to novel process for the preparation of nilotinib and the process for the preparation of intermediates for nilotinib viz. 4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzoic acid and 3-methyl-5-(4-methylimidazol-1-yl)aniline.
...
The present invention relates to an intravenous infusion dosage form of morphine which is autoclavable and has prolonged stability at room temperature.
Terminal sterilization by autoclaving provides highest assurance of sterility for parenteral dosage forms. However, preparation of a ready-to-infuse intravenous dos...
The present invention relates to oral liquid compositions of Guanfacine. The liquid
compositions can be immediate release or extended release compositions. The compositions
comprise Guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the
composition. The liquid compositions can be in the for...
The present invention relates to a dual-chamber pack comprising a first chamber prefilled
with a suspension base and a second chamber prefilled with a powder for suspension comprising an active ingredient, wherein upon activation of the dual-chamber pack, the contents of both the
chambers are mixed to form an exte...
The present invention relates to extended release liquid compositions of metformin. The
extended release liquid compositions are in the form of suspensions or reconstituted powder for
suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein...
The present invention relates to a dual chamber pack comprising a first chamber prefilled with a suspension base and a second chamber prefilled with a powder for suspension comprising an active ingredient wherein upon activation of the dual chamber pack the contents of both the chambers are mixed to form an extended...
The present invention relates to once-daily oral pharmaceutical composition of isotretinoin and a process for its preparation.
The present invention relates to extended release liquid compositions of guaifenesin. The extended release liquid compositions are in the form of suspensions which are ready-to-use or suspensions which are reconstituted from powder. It also relates to processes for the preparation of said extended release liquid com...
The present invention relates to an intravenous infusion dosage form of pemetrexed which is autoclavable and has prolonged stability at room temperature.
Pemetrexed undergoes degradation via different mechanisms, like oxidation, hydrolysis, dimerization and others that are unknown and not yet elucidated. In view of...
A dispensing pack having a container filled with a powder composition comprising clotrimazole and an angular cap fitted onto the container. The angular cap is having chimneys with channels for outflow of the powder from the container. The dispensing pack of the present invention offers the advantages of reduced risk...
The present invention relates to a storage stable aqueous solution of carboplatin and a parenteral dosage form containing it. Carboplatin is commercially available in the form of lyophilized powder or pre-concentrate solutions, which requires reconstitution and dilution. The reconstituted solutions are merely stable...
The present invention relates to a stable parenteral unit dosage form of dihydroergotamine or its pharmaceutically acceptable salt. Formulating dihydroergotamine or its pharmaceutically acceptable salt as an aqueous solution is difficult due to stability issue and generation of impurities. There is a need to develop...
The present invention relates to extended release liquid compositions of guanfacine. The extended release liquid compositions of the present invention are bioequivalent to marketed extended release tablet compositions of guanfacine. Said extended release liquid compositions provide substantially similar in-vitro dis...
The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon st...
The present invention relates to an improved process for the preparation of eluxadoline and its intermediates and that includes the use of an aqueous surfactant solution in the preparation of N2-[(benzyloxy)carbonyl]-N-(2-oxo-2-phenylethyl)-L-alaninamide an intermediate in the preparation of eluxadoline.
...
The present invention relates to processes for the preparation of eluxadoline. The present invention also provides a compound of Formula V a process for its preparation and its use for the preparation of eluxadoline.
ABSTRACT
The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The inventi...
ABSTRACT
EXTRACT OF COCCULUS HIRSUTUS FOR TREATMENT OF COVID-19
The present disclosure provides an extract of Cocculus hirsutus for prophylactic and/or curative treatment of an infection caused by SARS-CoV-2 virus. The invention also provides a stable pharmaceutical composition comprising the said extract. The p...
The present disclosure provides an extract of Cocculus hirsutus for prophylactic and/or curative treatment of an infection caused by SARS-CoV-2 virus. The disclosure also provides a stable pharmaceutical composition comprising the said extract. The present disclosure also provides a method for reducing viral load an...
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivative...
ABSTRACT
DULOXETINE SPRINKLES
The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates ...
The present invention provides a parenteral dosage form consisting essentially of a solution 5 filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to ...
The present invention relates to an intravenous infusion dosage form of pemetrexed which is autoclavable and has prolonged stability at room temperature. Pemetrexed undergoes degradation via different mechanisms, like oxidation, hydrolysis, dimerization and others that are unknown and not yet elucidated. In view of ...
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to the stable nanomicellar solution comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporin...
A method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration.
ABSTRACT
FIXED DOSE ANTI-DIABETIC PHARMACEUTICAL COMPOSITION
The present invention relates to a fixed dose pharmaceutical composition comprising a combination of sitagliptin, metformin and glimepiride or their pharmaceutically acceptable salt thereof, wherein the composition does not show any hypoglycemic effect...
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
This disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of psoriatic arthritis.
ABSTRACT
STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to the stable nanomicellar solution comprising cyclosporine form with ch...
The present disclosure relates to a ready-to-use or a ready to administer parenteral dosage form of oxytocin or a pharmaceutically acceptable salt thereof comprising a ready-to-infuse, stable aqueous solution of oxytocin or a pharmaceutically acceptable salt thereof. The solution can be administered to a patient in ...
ABSTRACT
SUSTAINED RELEASE COMPOSITION OF PROGESTERONE
The present invention relates to a sustained-release oral dosage form of Progesterone or its pharmaceutically acceptable salts thereof. The sustained release composition according to present invention is for once daily administration would be consistent wi...
The present invention relates to an aqueous, sterile ophthalmic solution of low strength atropine sulfate, which is storage stable. Particularly, the present invention provides a stable, aqueous, sterile solution of atropine sulfate for ophthalmic use, filled in a light protective container, said solution comprising...
ABSTRACT
EXTENDED RELEASE CEFPODOXIME PROXETIL COMPOSITION
The present invention relates to an improved stable extended-release composition of cefpodoxime and a process for its preparation. The composition comprises cefpodoxime proxetil, a stabilizer, and a release-controlling agent, wherein the composition is c...
The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous s...
The present invention relates to a stable parenteral dosage form with a ready-to-inject sterile stable aqueous solution of cetrorelix acetate. The invention also relates to an injection device prefilled with the ready-to-inject sterile stable aqueous solution of cetrorelix acetate. The present invention relates a me...
A process is described for the preparation of substantially pure fluvoxamine maleate, an important antidepressant drug of the formula i, for use as an active pharmaceutical ingredient (api), from the corresponding oxime viz.5-methoxy-4'-trifluoromethy valerophenone oxime of formula II. ...
A solid oral dosage form comprising therapeutically effective amount of afatinib or a salt thereof and an acid in an amount sufficient to provide an acidic microenvironment of pH less than 3.5, wherein the solid dosage form is a dry solid dosage form and wherein when the solid oral dosage form is stored at condition...
The present invention provides a crystalline form of baricitinib a process for its preparation a pharmaceutical composition comprising it and its use for the treatment of JAK associated diseases.
The present invention provides a process for the preparation of 4 dimethylaminocrotonic acid of Formula (II) or its salts which is used as an intermediate for the preparation of afatinib or its salts.
The present invention provides an oral pharmaceutical composition of isotretinoin having
enhanced bioavailability. The present invention further relates to a process for preparing the oral
pharmaceutical composition of the present invention.
The present invention relates to a dual-chamber pack with a first chamber comprising a container; and a second chamber comprising a reservoir, a biphasic connector, a plunger, and a plug with a breakable polymeric membrane. The container of the first chamber is prefilled with a pharmaceutically acceptable vehicle an...
ABSTRACT
The present invention relates to an aqueous, sterile ophthalmic solution of low strength atropine sulfate, which is storage stable. Till date, before the priority date of the present invention, instability of low dose aqueous solution of atropine is an unresolved problem. Aqueous solutions show problem o...
ABSTRACT
SUSTAINED RELEASE READY TO USE SUSPENSION COMPRISING DEXTROMETHORPHAN
The present disclosure provides a ready to use, stable sustained release liquid oral suspension formulation comprising dextromethorphan polistirex granules coated with a semi-permeable membrane, chlorpheniramine polistirex granules and ...
ABSTRACT
A PROCESS FOR THE PREPARATION OF CARIPRAZINE SALT
The present invention provides an improved process for preparation of cariprazine hydrochloride through the formation of other acid addition salts of cariprazine; wherein the process comprises reaction of trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-y...
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corticosteroid for use in the treatment of plaque psoriasis.
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the pre...
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporin...
ABSTRACT
EXTENDED RELEASE CEFPODOXIME PROXETIL COMPOSITION
The present invention relates to a stable extended-release composition of cefpodoxime and a process for its preparation. The composition comprises cefpodoxime proxetil, a stabilizer, and a release-controlling agent, wherein the composition is characteriz...
A parenteral dosage form of diltiazem, comprising a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, a pharmaceutically acceptable stabilizer selected from cyclic oligosaccharides, and an infusion container fdled with the said aqueous solution.
...
The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
ABSTRACT
STABLE PHARMACEUTICAL COMPOSITION OF HISTAMINE H2-RECEPTOR ANTAGONIST
The present disclosure relates to a stable pharmaceutical composition comprising a Histamine H2-receptor antagonist or a pharmaceutically acceptable salt thereof and a stabilizing amount of at least one alkalizer. The composition prov...
The present invention relates to timed extended-release pharmaceutical compositions comprising metoprolol and an extended-release polymer. The pharmaceutical compositions of the present invention exhibit an in-vivo lag time of at least 2 hours
and a Tmax of more than 8 hours. Further, said pharmaceutical compositio...
The present invention relates to an aqueous composition of cholecalciferol. The present invention relates to an oil-free, stable, aqueous composition of cholecalciferol at a concentration ranging from 400 IU-600000 IU. The invention also includes process of preparing such compositions and use of such compositions fo...
The present disclosure relates to a stable multiparticulate composition comprising coated discrete units of an amine drug or a pharmaceutically acceptable salt thereof with stabilizing amount of one or more nitrite quencher. The composition provides effective control of the level of nitrosamine drug substance relat...
The present invention relates to crystalline forms of Pirtobrutinib, co-crystals comprising Pirtobrutinib and a co-crystal former, wherein the co-crystal former is selected from the group consisting of glutaric acid, oxalic acid, and L-tryptophan, processes for their preparation, pharmaceutical formulations, and the...
The invention relates to stable compositions of an antibody against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. The present invention relates to pharmaceutical compositions o...
Registered Trademarks
[Class : 5] Medicinal & Pharmaceutical Preparations
[Class : 5] Pharmaceutical And Medicinal Preparations, Herbal Medicines; Hygienic & Sanitary Preparations For Medical Purposes; Dietetic Food And Substances Adapted For Medical Uses; Dietary Supplements For Human Beings; Nutraceutical Preparations For Therapeutic Or Medical Purposes, Nutritional Supplements, Dietary Supplements Intended To Supplement A Normal Diet Or To Have...
[Class : 5] Pharmaceutical And Medicinal Preparations ; Medicated Skin Care Products And Preparations; Medicated Skin Care Creams And Lotions; Medicated Cosmetics Included In Class 5
View +2316 more Brands for Sun Pharmaceutical Industries Limited.
Charges
31 March 2012
Biotechnology Industry Research Assistance Council
17 Crore
26 May 1999
Nvfc Finance Private Ltd
75 Lak
29 April 1999
Risk Capital And Technology Finance Corporation Ltd
1 Crore
17 November 1998
Industrial Development Bank Of India
3 Crore
13 September 1996
Industrial Development Bank Of India
9 Crore
11 October 1993
Gujarat Industrial Investment Corporation Ltd.
1 Crore
03 July 1995
Icici Bank Limited
126 Crore
06 April 1993
Bank Of Baroda
8 Crore
03 July 1995
Bank Of Baroda
25 Crore
28 January 1995
Bank Of Baroda
17 Crore
03 July 1995
Bank Opf Baroda
25 Crore
28 June 1995
Bank Of Baroda
17 Crore
03 July 2002
Standard Chartered Bank
48 Crore
21 September 1996
Anz Grindlays Bank Ltd.
7 Crore
29 June 2001
Abn Amro Bnak N V
72 Crore
24 October 2003
State Bank Of India
300 Crore
05 October 1993
The Industrial Credit & Investment Corporation Of India Ltd.
4 Crore
25 October 1993
The S.c.i.c.i. Ltd.
2 Crore
07 May 1997
Icici Banking Corporation Ltd.
6 Crore
30 March 2001
Punjab National Ban K
212 Crore
09 April 2003
Credit Lyonnais
36 Crore
30 December 2005
Citi Bank N.a.
72 Crore
17 February 2003
Deutche Bank
30 Crore
24 October 2001
The Hongkong And Shanghai Banking Corporation Ltd
48 Crore
18 February 2013
Axis Trustee Services Limited
500 Crore
26 May 1999
Lakshdeep Investment & Finance Pvt Ltd
75 Lak
08 December 1998
Lakshdeep Investment & Finance Pvt Ltd
13 Crore
28 July 1994
Bank Of America
23 Crore
24 April 1991
Deutshe Bank A G
1 Crore
20 August 1999
Technology Development Board (department Of Science And T )
3 Crore
07 July 2000
The Bank Of Nova Scotia
8 Crore
22 May 2000
Icici Bank Limited
21 Crore
24 August 2000
The Bank Of Nova Scona
5 Lak
14 September 1997
Bank Of Baroda
15 Crore
13 October 1995
Anz Grindlays Bank
3 Crore
16 June 1998
Bank Of Baroda
67 Crore
15 May 1997
The Industrial Credit & Investment Corporation Of India Ltd.
40 Crore
05 October 1993
The Industrial Credit & Investemnt Corporation Of India Ltd.
4 Crore
23 September 1998
Icici Limited
25 Crore
31 March 2012
Others
0
28 June 1995
Bank Of Baroda
0
29 April 1999
Risk Capital And Technology Finance Corporation Ltd
0
29 June 2001
Abn Amro Bnak N V
0
13 October 1995
Anz Grindlays Bank
0
20 August 1999
Technology Development Board (department Of Science And T )
0
25 October 1993
The S.c.i.c.i. Ltd.
0
03 July 1995
Bank Opf Baroda
0
17 November 1998
Industrial Development Bank Of India
0
08 December 1998
Lakshdeep Investment & Finance Pvt Ltd
0
16 June 1998
Bank Of Baroda
0
24 October 2003
State Bank Of India
0
24 August 2000
The Bank Of Nova Scona
0
07 July 2000
The Bank Of Nova Scotia
0
26 May 1999
Nvfc Finance Private Ltd
0
26 May 1999
Lakshdeep Investment & Finance Pvt Ltd
0
07 May 1997
Icici Banking Corporation Ltd.
0
28 January 1995
Bank Of Baroda
0
30 March 2001
Punjab National Ban K
0
09 April 2003
Credit Lyonnais
0
17 February 2003
Deutche Bank
0
03 July 2002
Standard Chartered Bank
0
24 April 1991
Deutshe Bank A G
0
23 September 1998
Icici Limited
0
03 July 1995
Bank Of Baroda
0
11 October 1993
Gujarat Industrial Investment Corporation Ltd.
0
05 October 1993
The Industrial Credit & Investemnt Corporation Of India Ltd.
0
22 May 2000
Icici Bank Limited
0
15 May 1997
The Industrial Credit & Investment Corporation Of India Ltd.
0
21 September 1996
Anz Grindlays Bank Ltd.
0
03 July 1995
Icici Bank Limited
0
05 October 1993
The Industrial Credit & Investment Corporation Of India Ltd.
0
06 April 1993
Bank Of Baroda
0
14 September 1997
Bank Of Baroda
0
13 September 1996
Industrial Development Bank Of India
0
30 December 2005
Citi Bank N.a.
0
24 October 2001
The Hongkong And Shanghai Banking Corporation Ltd
0
18 February 2013
Axis Trustee Services Limited
0
31 March 2012
Others
0
28 June 1995
Bank Of Baroda
0
29 April 1999
Risk Capital And Technology Finance Corporation Ltd
0
29 June 2001
Abn Amro Bnak N V
0
13 October 1995
Anz Grindlays Bank
0
20 August 1999
Technology Development Board (department Of Science And T )
0
25 October 1993
The S.c.i.c.i. Ltd.
0
03 July 1995
Bank Opf Baroda
0
17 November 1998
Industrial Development Bank Of India
0
08 December 1998
Lakshdeep Investment & Finance Pvt Ltd
0
16 June 1998
Bank Of Baroda
0
24 October 2003
State Bank Of India
0
24 August 2000
The Bank Of Nova Scona
0
07 July 2000
The Bank Of Nova Scotia
0
26 May 1999
Nvfc Finance Private Ltd
0
26 May 1999
Lakshdeep Investment & Finance Pvt Ltd
0
07 May 1997
Icici Banking Corporation Ltd.
0
28 January 1995
Bank Of Baroda
0
30 March 2001
Punjab National Ban K
0
09 April 2003
Credit Lyonnais
0
17 February 2003
Deutche Bank
0
03 July 2002
Standard Chartered Bank
0
24 April 1991
Deutshe Bank A G
0
23 September 1998
Icici Limited
0
03 July 1995
Bank Of Baroda
0
11 October 1993
Gujarat Industrial Investment Corporation Ltd.
0
05 October 1993
The Industrial Credit & Investemnt Corporation Of India Ltd.
0
22 May 2000
Icici Bank Limited
0
15 May 1997
The Industrial Credit & Investment Corporation Of India Ltd.
0
21 September 1996
Anz Grindlays Bank Ltd.
0
03 July 1995
Icici Bank Limited
0
05 October 1993
The Industrial Credit & Investment Corporation Of India Ltd.
0
06 April 1993
Bank Of Baroda
0
14 September 1997
Bank Of Baroda
0
13 September 1996
Industrial Development Bank Of India
0
30 December 2005
Citi Bank N.a.
0
24 October 2001
The Hongkong And Shanghai Banking Corporation Ltd
0
18 February 2013
Axis Trustee Services Limited
0
31 March 2012
Others
0
28 June 1995
Bank Of Baroda
0
29 April 1999
Risk Capital And Technology Finance Corporation Ltd
0
29 June 2001
Abn Amro Bnak N V
0
13 October 1995
Anz Grindlays Bank
0
20 August 1999
Technology Development Board (department Of Science And T )
0
25 October 1993
The S.c.i.c.i. Ltd.
0
03 July 1995
Bank Opf Baroda
0
17 November 1998
Industrial Development Bank Of India
0
08 December 1998
Lakshdeep Investment & Finance Pvt Ltd
0
16 June 1998
Bank Of Baroda
0
24 October 2003
State Bank Of India
0
24 August 2000
The Bank Of Nova Scona
0
07 July 2000
The Bank Of Nova Scotia
0
26 May 1999
Nvfc Finance Private Ltd
0
26 May 1999
Lakshdeep Investment & Finance Pvt Ltd
0
07 May 1997
Icici Banking Corporation Ltd.
0
28 January 1995
Bank Of Baroda
0
30 March 2001
Punjab National Ban K
0
09 April 2003
Credit Lyonnais
0
17 February 2003
Deutche Bank
0
03 July 2002
Standard Chartered Bank
0
24 April 1991
Deutshe Bank A G
0
23 September 1998
Icici Limited
0
03 July 1995
Bank Of Baroda
0
11 October 1993
Gujarat Industrial Investment Corporation Ltd.
0
05 October 1993
The Industrial Credit & Investemnt Corporation Of India Ltd.
0
22 May 2000
Icici Bank Limited
0
15 May 1997
The Industrial Credit & Investment Corporation Of India Ltd.
0
21 September 1996
Anz Grindlays Bank Ltd.
0
03 July 1995
Icici Bank Limited
0
05 October 1993
The Industrial Credit & Investment Corporation Of India Ltd.
0
06 April 1993
Bank Of Baroda
0
14 September 1997
Bank Of Baroda
0
13 September 1996
Industrial Development Bank Of India
0
30 December 2005
Citi Bank N.a.
0
24 October 2001
The Hongkong And Shanghai Banking Corporation Ltd
0
18 February 2013
Axis Trustee Services Limited
0
Documents
Form MGT-6-03042021_signed
Optional Attachment-(2)-31122020
Optional Attachment-(1)-31122020
-31122020
Form MGT-6-07122020_signed
-04122020
Optional Attachment-(1)-04122020
Optional Attachment-(2)-04122020
Form MGT-6-03122020_signed
Optional Attachment-(1)-02122020
-02122020
Form MSME FORM I-30102020_signed
Shareholders-MGT_7_R68282409_MEETAL2008_20201030160554.xlsm
Form MGT-7-23102020_signed
Optional Attachment-(2)-22102020
Optional Attachment-(1)-22102020
Copy of MGT-8-22102020
Form AOC-4(XBRL)-28092020-signed
Optional Attachment-(1)-25092020
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-25092020
Form MGT-14-25092020_signed
Form MGT-15-24092020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-23092020
Form MGT-6-11092020_signed
-10092020
Optional Attachment-(1)-10092020
Form MGT-6-04092020_signed
-03092020
Optional Attachment-(1)-03092020
Form MGT-6-19082020_signed
